Back
ESC Professional Premium Access

Investigational randomized controlled trial of patients with inoperable chronic thromboembolic pulmonary hypertension treated with riociguat vs selexipag

Session: Pulmonary arterial hypertension: general (3)
Topic: Pulmonary Hypertension
Speaker: Assistant Professor Y. Nakano (Nagoya, JP)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Assistant Professor Yoshihisa Nakano

Nagoya University Hospital, Nagoya (Japan)
0 follower

6 more presentations in this session

SGLT2i downregulate the activin/inhibin and miR-1306-5p signaling pathways in patients with HFrEF and associated pulmonary hypertension: a prospective intervention study

Speaker: Doctor M. Alberti (Pisa, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Insulin resistance indices are associated with the presence and outcomes of pulmonary hypertension due to left heart failure

Speaker: Doctor R. Quan (Beijing, CN)

Access
Abstract
Slides
Video
Like
Thumbnail

Left atrial V-wave as a potential new pathophysiological trigger of pulmonary hypertension

Speaker: Doctor F. Bauer (Le Kremlin-Bicetre, FR)

Access
Abstract
Slides
Video
Like
Thumbnail

Early CMR-derived markers of right ventricular involvement in combined post- and pre-capillary pulmonary hypertension

Speaker: Doctor C. Perez Garcia (Madrid, ES)

Access
Abstract
Slides
Video
Like
Thumbnail

Mapping right ventricular adaptation in pulmonary arterial hypertension: insights from a six-phenotype model

Speaker: Doctor A. Lescano (Buenos Aires, AR)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Pulmonary arterial hypertension: general (3)

Speakers: Assistant Professor Y. Nakano, Doctor M. Alberti, Doctor R. Quan, Doctor F. Bauer, Doctor C. Perez Garcia...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

novartis Explore sponsored resources